<DOC>
	<DOCNO>NCT00228956</DOCNO>
	<brief_summary>You invite participate research study look metabolism ( breakdown ) effect aromatase inhibitor . The purpose research try identify woman take aromatase inhibitor likely certain benefit side effect drug . We determine whether difference normally occur gene inherit parent might influence way individual respond medication . If agree participate study , ask sign inform consent form .</brief_summary>
	<brief_title>Aromatase Inhibitor Clinical Trial</brief_title>
	<detailed_description>Primary Objective To determine baseline breast density change parameter occur post-menopausal woman hormone-receptor positive primary breast cancer take letrozole exemestane 24 month , correlate change wild type variant aromatase ( CYP19 ) . Secondary Objectives 1 . To determine serum estrone sulfate concentration baseline follow one , three 24 month letrozole exemestane therapy . We use concentration test hypothesis candidate gene involve estrogen metabolism post-menopausal woman , metabolism disposition exemestane letrozole , influence ability aromatase inhibitor reduce estrogen metabolite concentration . 2 . To determine bone density bone turnover metabolites post-menopausal woman . The bone densitometry do baseline follow 24 month letrozole exemestane therapy . The bone turnover metabolites do baseline , three , six 24 month follow letrozole exemestane therapy . These data allow u test hypothesis variant candidate gene involve estrogen metabolism signal alter ability exemestane letrozole bring change bone . 3 . To objectively measure hot flash baseline monitor change hot flash one , three , six 12 month letrozole exemestane therapy , correlate change serum FSH LH concentration . We test hypothesis aromatase estrogen receptor variant influence phenotype hot flash baseline treatment part broad approach test association candidate gene involve estrogen metabolism signal , aromatase inhibitor metabolism disposition . 4 . To measure change symptom may relate hot flash estrogen deprivation menopausal symptom , mood ( depression , anxiety ) , sleep quality sleep disturbance overall quality life baseline one , three , six , twelve 24 month treatment . 5 . To measure change fast lipid profile baseline 3 month letrozole exemestane therapy . 6 . To determine letrozole exemestane serum concentration baseline one , three , six , twelve 24 month treatment test hypothesis genetic variant drug metabolize enzyme predict drug concentration effect . 7 . To measure serum thyroid bind globulin sex hormone bind globulin concentration one three month treatment , test whether change parameter bring aromatase inhibitor treatment alter genetic variant candidate gene involve estrogen metabolism signal . 8 . To categorize rheumatic adverse effect experience patient aromatase inhibitor specifically characterize anatomic structure involve document presence absence inflammation tissue ; identify correlation change musculoskeletal symptom duration therapy aromatase inhibitor ; identify correlation change musculoskeletal symptom level circulate estrogen metabolite . This do baseline one , three , six , twelve 24 month treatment . 9 . To determine number specific platelet function 3 month letrozole exemestane treatment . This sub-study perform Indiana University site . Platelet function measure ex vivo platelet aggregation test . Production regulator platelet function , include thromboxane A2 ( TXA2 ) , proscyclin ( PGI2 ) serotonin also assess . These data allow u test hypothesis genetic polymorphism candidate gene estrogen-regulated pathway alter effect letrozole exemestane treatment platelet activity , may relevant effect cardiac risk .</detailed_description>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>1 . Female gender . 2 . Postmenopausal status , define : age &gt; 60 ; less age 60 last menstrual period &gt; 12 month prior enrollment trial intact uterus/ovaries ; , less age 60 last menstrual period 612 month prior enrollment trial intact uterus/ovaries meet biochemical criterion menopause ( FSH estradiol level within institutional standard menopausal status ) NOTE : These subject serum estradiol level check visit 0 , 1 , 3 , 6 12 month check continue menopausal status ; , less age 60 history bilateral oophorectomy ; , less age 60 history hysterectomy meet biochemical criterion menopause ( FSH estradiol level within institutional standard menopausal status ) . NOTE : These subject serum estradiol level check visit 0 , 1 , 3 , 6 12 month check continue menopausal status ; , less age 60 take medication design suppress ovarian function meet biochemical criterion menopause ( estradiol level within institutional standard menopausal status ) . Women would take drug least 30 day prior enter study . NOTE : While patient treat GnRh agonist ( luprolide goserelin ) , serum estradiol level check visit 0 , 1 , 3 , 6 12 month check menopausal status . 3 . Patients histologically proven ductal carcinoma situ ( DCIS/stage 0 ) stage IIII invasive carcinoma breast ER and/or PR positive immunohistochemical staining , consider aromatase inhibitor therapy . Patients must complete adjuvant chemotherapy . Patients may receive preoperative chemotherapy . Patients also complete local therapy ; however , enrollment/initiation aromatase inhibitor study may do prior completion radiation therapy . Women may receive aromatase inhibitor study initial adjuvant hormonal treatment follow adjuvant tamoxifen . 4 . ECOG performance status 02 . 5 . The patient aware nature diagnosis , understand study regimen , requirement , risk , discomfort , able willing sign inform consent form . 1 . History bilateral mastectomy . 2 . History radiation contralateral breast . 3 . Prior use aromatase inhibitor . 4 . Personal history follow cancer : ovarian , endometrial , fallopian tube primary peritoneal carcinomatosis . 5 . Presence implant contralateral breast . 6 . Women history breast reduction enter discretion investigator . Breast reduction two year trial strongly discourage .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Aromatase Inhibitor</keyword>
	<keyword>Letrozole</keyword>
	<keyword>Exemestane</keyword>
</DOC>